1-17 of 17
Marcin Kowanetz
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract 2911: The CEA-targeted ISAC, BDC-2034, shows preclinical efficacy associated with innate immune activation, phagocytosis, and myeloid reprogramming

Lisa K. Blum, Cecelia I. Pearson, Laughing Bear Torrez Dulgeroff, Rishali Gadkari, Angela Luo, Andrew Luo, Jennifer E. Melrose, Jess L. Nolin, Hai Li, Arthur Lee, Matthew N. Zhou, Puneet Anand, Ganapathy Sarma, Karla A. Henning, Steven J. Chapin, Shelley E. Ackerman, Romas Kudirka, Yuyi Shen, Bruce Hug, Edith A. Perez, Marcin Kowanetz, Michael N. Alonso, Brian S. Safina, David Dornan, William G. Mallet
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 2911.
DOI: https://doi.org/10.1158/1538-7445.AM2022-2911
Published: 15 June 2022
View article
Journal Articles

Abstract 2883: Dectin-2 agonist antibodies reprogram tumor-associated macrophages to drive anti-tumor immunity

Justin A. Kenkel, Po Y. Ho, Karla A. Henning, Cindy L. Kreder, Jess L. Nolin, Sameera Kongara, Steven J. Chapin, Amreen Husain, Marcin Kowanetz, Edgar G. Engleman, Michael N. Alonso, David Dornan, Shelley E. Ackerman
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 2883.
DOI: https://doi.org/10.1158/1538-7445.AM2022-2883
Published: 15 June 2022
View article
Journal Articles

Abstract 4252: PD-L1-targeted ISAC combines myeloid cell activation, immune-checkpoint inhibition and ADCP to improve anti-tumor efficacy over anti-PD-L1 antibodies in preclinical models

Justin A. Kenkel, Rishali Gadkari, Po Y. Ho, Lisa K. Blum, Romas Kudirka, Karla A. Henning, William G. Mallet, Jennifer E. Melrose, Ganapathy Sarma, Steven J. Chapin, Matthew Zhou, Suprit Deol, Cindy Kreder, Yuyi Shen, Bruce Hug, Puneet Anand, Arthur Lee, Hai Li, Shelley E. Ackerman, Brian S. Safina, David Dornan, Michael N. Alonso, Marcin Kowanetz
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 4252.
DOI: https://doi.org/10.1158/1538-7445.AM2022-4252
Published: 15 June 2022
View article
Journal Articles

Abstract CT218: Phase 1/2 study of a novel HER2 targeting TLR7/8 immune-stimulating antibody conjugate (ISAC), BDC-1001, alone and in combination with pembrolizumab (pembro) in patients (pts) with HER2-expressing advanced solid tumors

Manish R. Sharma, Richard D. Carvajal, Daniel Catenacci, Leisha A. Emens, Glenn J. Hanna, Dejan Juric, Yoon-Koo Kang, Jeeyun Lee, Keun-Wook Lee, Bob T. Li, Kathleen Moore, Mark D. Pegram, Paula R. Pohlmann, Drew Rasco, Alexander Spira, Arielle L. Heeke, Ding Wang, Lawrence Garbo, Sudhir Manda, Jasgit Sachdev, Shelley E. Ackerman, Heidi LeBlanc, David Dornan, Marcin Kowanetz, Michael N. Alonso, Amreen Husain, Edith A. Perez, Ecaterina Ileana Dumbrava
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): CT218.
DOI: https://doi.org/10.1158/1538-7445.AM2021-CT218
Published: 01 July 2021
View article
Journal Articles

Abstract OT-03-02: Phase 1/2 study of a novel HER2 targeting TLR7/8 immune-stimulating antibody conjugate (ISAC), BDC-1001, as a single agent and in combination with an immune checkpoint inhibitor in patients with advanced HER2-expressing solid tumors

Ecaterina Ileana Dumbrava, Manish R. Sharma, Richard D. Carvajal, Daniel Catenacci, Leisha A. Emens, Shirish M. Gadgeel, Glenn J. Hanna, Dejan Juric, Yoon-Koo Kang, Jeeyun Lee, Keun-Wook Lee, Bob T. Li, Kathleen Moore, Mark D. Pegram, Paula R. Pohlmann, Drew Rasco, Alexander Spira, Antoinette R. Tan, Shelley E. Ackerman, Heidi LeBlanc, David Dornan, Marcin Kowanetz, Michael N. Alonso, Edith A. Perez
Journal: Cancer Research
Cancer Res (2021) 81 (4_Supplement): OT-03-02.
DOI: https://doi.org/10.1158/1538-7445.SABCS20-OT-03-02
Published: 15 February 2021
View article
Journal Articles

Abstract CT200: IMpower130: Progression-free survival (PFS) and safety analysis from a randomized phase 3 study of carboplatin + nab-paclitaxel (CnP) with or without atezolizumab as first-line (1L) therapy in advanced non-squamous NSCLC

Howard L. West, Michael McCleod, Maen Hussein, Alessandro Morabito, Achim Rittmeyer, Henry J. Conter, Hans-Georg Kopp, Davey Daniel, Steven McCune, Tarek Mekhail, Alona Zer, Niels Reinmuth, Ahad Sadiq, Venice Archer, Tania Ochi Lohmann, Helen Jessop, Lijia Wang, Marcin Kowanetz, Alan Sandler, Federico Cappuzzo
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): CT200.
DOI: https://doi.org/10.1158/1538-7445.AM2019-CT200
Published: 01 July 2019
View article
Journal Articles

Abstract CT076: IMpower150: Efficacy of atezolizumab (atezo) plus bevacizumab (bev) and chemotherapy (chemo) in 1L metastatic nonsquamous NSCLC (mNSCLC) across key subgroups

Marcin Kowanetz, Mark A. Socinski, Wei Zou, Mark McCleland, Nancy Yang, Ariel Lopez Chavez, Alexander Spira, Julien Mazières, Fadi Braiteh, David Shames, Alan Sandler, Martin Reck
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): CT076.
DOI: https://doi.org/10.1158/1538-7445.AM2018-CT076
Published: 01 July 2018
View article
Journal Articles

Abstract 5706: A blood-based next-generation sequencing assay to determine tumor mutational burden (bTMB) is associated with benefit to an anti-PD-L1 inhibitor, atezolizumab

David Fabrizio, Daniel Lieber, Christine Malboeuf, Jacob Silterra, Emily White, Michael Coyne, Tina Brennan, Jie Ma, Mark Kennedy, Erica Schleifman, Sarah Paul, Yan Li, David Shames, Craig Cummings, Eric Peters, Marcin Kowanetz, Doron Lipson, Geoff Otto
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): 5706.
DOI: https://doi.org/10.1158/1538-7445.AM2018-5706
Published: 01 July 2018
View article
Journal Articles

Abstract 5707: On-treatment changes in CRP as a surrogate for overall survival for atezolizumab benefit in 2nd line NSCLC

Namrata Patil, Wei Zou, Simonetta Mocci, Vinita Gupta, Luciana Molinero, Alan Sandler, Marcus Ballinger, Susan Flynn, Marcin Kowanetz, Priti Hegde
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): 5707.
DOI: https://doi.org/10.1158/1538-7445.AM2018-5707
Published: 01 July 2018
View article
Journal Articles

Abstract 2987: Validation and clinical feasibility of a comprehensive genomic profiling assay to identify likely immunotherapy responders through tumor mutational burden (TMB)

Daniel S. Lieber, Mark R. Kennedy, Douglas B. Johnson, Jonathan E. Rosenberg, Marcin Kowanetz, Joel R. Greenbowe, Garrett M. Frampton, Caitlin F. Connelly, Alexa B. Schrock, Jeffrey S. Ross, Philip J. Stephens, Siraj M. Ali, Vincent A. Miller, David A. Fabrizio
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): 2987.
DOI: https://doi.org/10.1158/1538-7445.AM2017-2987
Published: 01 July 2017
View article
Journal Articles

Abstract 5117: An automated 5-plex fluorescent immunohistochemistry enabled characterization of PD-L1 expression and tumor infiltrating immune cells in lung and bladder cancer specimens

Wenjun Zhang, Antony Hubbard, Adriana Racolta, Nick Cummins, Mehrnoush Khojasteh, Liping Zhang, Karl Garsha, Joerg Bredno, Dustin Harshman, Srabani Bhaumik, Tobin Jones, Marcin Kowanetz, Sanjeev Mariathasan, Ian McCaffery, Dustin Smith, J Andrew Williams, Lidija Pestic-Dragovich, Larry Morrison, Lei Tang
Journal: Cancer Research
Cancer Res (2016) 76 (14_Supplement): 5117.
DOI: https://doi.org/10.1158/1538-7445.AM2016-5117
Published: 15 July 2016
View article
Journal Articles

Abstract 2941: Local tumor irradiation combined with α-PDL-1 immune checkpoint inhibition results in local and systemic anti-tumor responses: Successful translation of a mouse model to a human case series

Idit Sagiv-Barfi, Amanda Rajapaksa, Debra Czerwinski, Serena Chang, Jonathan Hebb, Cariad Chester, Erin Waller, Gregg Fine, Daniel Chen, Marcin Kowanetz, Bryan Irving, Ronald Levy, Holbrook Kohrt
Journal: Cancer Research
Cancer Res (2014) 74 (19_Supplement): 2941.
DOI: https://doi.org/10.1158/1538-7445.AM2014-2941
Published: 01 October 2014
View article
Journal Articles

Abstract LB-288: A phase I study of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors.

Michael S. Gordon, Omid Hamid, John Powderly, Maria Anderson, Gregg Fine, Ahmad Mokatrin, Marcin Kowanetz, Leabman Maya, Bryan A. Irving, Daniel S. Chen, F Stephen Hodi
Journal: Cancer Research
Cancer Res (2013) 73 (8_Supplement): LB-288.
DOI: https://doi.org/10.1158/1538-7445.AM2013-LB-288
Published: 15 April 2013
View article
Journal Articles

Abstract 4978: Lung cancers regulate the immune suppressor PD-L1 by multiple mechanisms, altering its role in tumor survival.

Edward (Ward) E. Kadel, Kimberly Walter, Rupal Desai, Juliet Carbon, Marigold Boe, David Shames, Marcin Kowanetz
Journal: Cancer Research
Cancer Res (2013) 73 (8_Supplement): 4978.
DOI: https://doi.org/10.1158/1538-7445.AM2013-4978
Published: 15 April 2013
View article
Journal Articles

Abstract 2382: Development of predictive biomarker gene expression signatures that associates with drug sensitivity and kinase activation in breast cancer.

Carol Lynn O'Brien, Yuanyuan Xiao, Jill Spoerke, Ling Huw, Priti Hegde, Marcin Kowanetz, Mark Lackner, Timothy Wilson
Journal: Cancer Research
Cancer Res (2013) 73 (8_Supplement): 2382.
DOI: https://doi.org/10.1158/1538-7445.AM2013-2382
Published: 15 April 2013
View article
Journal Articles

Abstract 2849: Pharmacodynamic biomarkers of anti-PD-L1 activity in pre-clinical mouse tumor models.

Marigold Boe, Mahrukh Huseni, Brittany Jiang, Hartmut Koeppen, Heather Maecker, Bryan Irving, Priti Hegde, Marcin Kowanetz
Journal: Cancer Research
Cancer Res (2013) 73 (8_Supplement): 2849.
DOI: https://doi.org/10.1158/1538-7445.AM2013-2849
Published: 15 April 2013
View article
Journal Articles

Abstract 1982: TGF-beta induced SIK cooperates with Smurf2 to negatively regulate type I receptor kinase signaling

Michael Vanlandewijck, Peter Lönn, Marcin Kowanetz, Katarzyna Kowanetz, Christer Bush, Carl-Henrik Heldin, Aristidis Moustakas
Journal: Cancer Research
Cancer Res (2011) 71 (8_Supplement): 1982.
DOI: https://doi.org/10.1158/1538-7445.AM2011-1982
Published: 15 April 2011
View article